p300 catalytic inhibition selectively targets IRF4 oncogenic activity in multiple myeloma (IRF4KD)
RNA-seq (gene expression) · human · 24 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 24 samples: 8 conditions, mostly in triplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple MyelomaCancer research · 2026
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE274597_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1147261 and SRA study SRP525925. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 24 samples.
How we read this: 8 replicated groups read from 24 sample titles; they account for 24 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8453388 MM1R_siIRF4_rep1 MM1R_siIRF4
- GSM8453389 MM1R_siIRF4_rep2 MM1R_siIRF4
- GSM8453390 MM1R_siIRF4_rep3 MM1R_siIRF4
- GSM8453391 MM1R_CTRL_rep1 MM1R_CTRL
- GSM8453392 MM1R_CTRL_rep2 MM1R_CTRL
- GSM8453393 MM1R_CTRL_rep3 MM1R_CTRL
- GSM8453394 KMS-12-BM_siIRF4_rep1 KMS-12-BM_siIRF4
- GSM8453395 KMS-12-BM_siIRF4_rep2 KMS-12-BM_siIRF4
- GSM8453396 KMS-12-BM_siIRF4_rep3 KMS-12-BM_siIRF4
- GSM8453397 KMS-12-BM_CTRL_rep1 KMS-12-BM_CTRL
- GSM8453398 KMS-12-BM_CTRL_rep2 KMS-12-BM_CTRL
- GSM8453399 KMS-12-BM_CTRL_rep3 KMS-12-BM_CTRL
- GSM8453400 MM1S_siIRF4_rep1 MM1S_siIRF4
- GSM8453401 MM1S_siIRF4_rep2 MM1S_siIRF4
- GSM8453402 MM1S_siIRF4_rep3 MM1S_siIRF4
- GSM8453403 MM1S_CTRL_rep1 MM1S_CTRL
- GSM8453404 MM1S_CTRL_rep2 MM1S_CTRL
- GSM8453405 MM1S_CTRL_rep3 MM1S_CTRL
- GSM8453406 KMS-12-PE_siIRF4_rep1 KMS-12-PE_siIRF4
- GSM8453407 KMS-12-PE_siIRF4_rep2 KMS-12-PE_siIRF4
- GSM8453408 KMS-12-PE_siIRF4_rep3 KMS-12-PE_siIRF4
- GSM8453409 KMS-12-PE_CTRL_rep1 KMS-12-PE_CTRL
- GSM8453410 KMS-12-PE_CTRL_rep2 KMS-12-PE_CTRL
- GSM8453411 KMS-12-PE_CTRL_rep3 KMS-12-PE_CTRL
- GSE274846 p300 catalytic inhibition selectively targets IRF4 oncogenic activity in multiple myeloma (MM1S_SOC) 45 samples shares p300, irf4, selectively, inhibition, catalytic, oncogenic, activity
- GSE274845 p300 catalytic inhibition selectively targets IRF4 oncogenic activity in multiple myeloma (RPMI8226_KB528_timeseries) 15 samples shares p300, irf4, selectively, inhibition, catalytic, oncogenic, activity
- GSE274841 p300 catalytic inhibition selectively targets IRF4 oncogenic activity in multiple myeloma (MM1S_KB528_timeseries) 15 samples shares p300, irf4, selectively, inhibition, catalytic, oncogenic, activity
- GSE274843 p300 catalytic inhibition selectively targets IRF4 oncogenic activity in multiple myeloma (PBMC_KB528_timeseries) 15 samples shares p300, irf4, selectively, inhibition, catalytic, oncogenic, activity
- GSE274596 p300 catalytic inhibition selectively targets IRF4 oncogenic activity in multiple myeloma (DF_pt) 6 samples shares p300, irf4, selectively, inhibition, catalytic, oncogenic, activity
- GSE307536 p300 catalytic inhibition selectively targets IRF4 oncogenic activity in multiple myeloma 164 samples shares p300, irf4, selectively, inhibition, catalytic, oncogenic, activity
- GSE274593 p300 catalytic inhibition selectively targets IRF4 oncogenic activity in multiple myeloma (MM1S_ChIP_KB528) 44 samples shares p300, irf4, selectively, inhibition, catalytic, oncogenic, activity
- GSE304253 Inhibition of p300/CREBBP catalytic activity drives context-dependent transcriptional activation in AML. [SLAM-Seq] 35 samples shares p300, inhibition, catalytic, activity
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.